Researchers from the University of Queensland’s Queensland Brain Institute (QBI) have reported a significant leap forward in the treatment of Alzheimer’s disease. Contrary to long-standing beliefs, their study suggests that targeting amyloid plaques, a hallmark of Alzheimer’s, may not be essential for cognitive improvement using ultrasound therapy.
The conventional approach in Alzheimer’s research has focused on opening the blood-brain barrier with microbubbles to activate microglia, cells in the brain that clear these amyloid plaques. However, Dr Gerhard Leinenga and Professor Jürgen Götz have found that using scanning ultrasound alone on mouse models can lead to considerable memory enhancement.
“This approach represents a significant step towards personalised, effective therapies for neurodegenerative disorders,” Dr Leinenga said. The study’s findings reveal that ultrasound’s cognitive benefits are likely a result of induced neuronal changes such as increased plasticity and improved brain networks. This suggests that the therapy enhances the brain’s resilience to amyloid plaques without necessarily clearing them.
Professor Götz noted that the effectiveness of ultrasound therapy varied with frequency. Higher frequencies were associated with superior cognitive outcomes, a revelation that holds potential implications for current clinical trials in Alzheimer’s patients. “By understanding the mechanisms underlying ultrasound therapy, we can tailor treatment strategies to maximise cognitive improvement in patients,” Dr Leinenga said.
The discovery by QBI researchers is pivotal, as it challenges the premise that amyloid plaque clearance is crucial for cognitive improvement in Alzheimer’s therapy. Instead, their findings highlight the direct effects of ultrasound on neurons. This raises questions about the direction of current therapeutic strategies and could lead to more effective treatment approaches that don’t rely solely on targeting amyloid buildup.
The breakthrough comes amid a broader discussion in the medical community about the efficacy and cost-effectiveness of Alzheimer’s drugs like aducanumab and lecanemab. These drugs have stirred debate due to their high costs and modest impact on cognitive function. In the most recent Phase III findings, lecanemab demonstrated a 27% reduction in the rate of cognitive decline over an 18-month period among participants with early-stage Alzheimer’s disease. Additionally, research indicates that low-intensity focused ultrasound, guided by MRI, has the potential to open the blood-brain barrier, thereby enhancing the delivery of aducanumab to specific regions of the brain.
Nevertheless, the University of Queensland study stands out by demonstrating that ultrasound therapy itself, without the aid of drug treatments, may be a promising pathway for cognitive improvement in Alzheimer’s patients. And ultrasound treatment could offer a non-invasive and more accessible alternative.
Relevant articles:
– Ultrasound therapy shows promise as a treatment for Alzheimer’s disease
– Australia suggests use of ultrasound therapy as promising treatment for Alzheimer’s disease, BSA bureau, Tue, 02 Apr 2024 05:46:00 GMT
– Ultrasound Opens Blood Brain Barrier to Improve Alzheimer’s Drug’s Effects, Inside Precision Medicine, Thu, 04 Jan 2024 08:00:00 GMT
– Innovative Use of Ultrasound Could Enhance Alzheimer’s Treatment, Medriva, Mon, 08 Jan 2024 08:00:00 GMT